Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01472627 · ClinicalTrials.gov registry record
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 11
- Enrollment target
NCT01472627: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT01472627 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01472627 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
Primary Outcome
Whether treatment with bortezomib reverses measures of tumor mediated immune suppression proving an improved platform for tumor specific immunotherapy
Interventions
- PROCEDURE Blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-10 |
| Est. Completion | 2018-01 |
What the finished NCT01472627 record still lists
NCT01472627 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draws is the first listed.
NCT01472627 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01472627 about?
NCT01472627 is a clinical study titled "Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro". The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
What is the current status of trial NCT01472627?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2010-10. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01472627?
The interventions under investigation include: Blood draws (PROCEDURE).
Who is sponsoring clinical trial NCT01472627?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia